SCHEMBL20738486

SCHEMBL20738486

Cc1csc(C(C)(C)I)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
NOS1 P29475 1/20 0.43
SSTR4 P31391 1/20 0.39
GAA P10253 4/20 0.33
RAB9A P51151 4/20 0.33
KMT2A Q03164 4/20 0.33
NPC1 O15118 3/20 0.33
MAPK1 P28482 2/20 0.33
MEN1 O00255 3/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP3A4 P08684 2/20 0.33
HSD17B10 Q99714 2/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33
HPGD P15428 1/20 0.33
PDE10A Q9Y233 1/20 0.32
GRM5 P41594 1/20 0.32
MAPT P10636 3/20 0.32
CYP2E1 P05181 1/20 0.32
CYP2A6 P11509 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279632 0.81 SMN1; SMN2 (0.46) SMN1; SMN2NOS1SSTR4GAARAB9A
SCHEMBL12818069 0.79 SMN1; SMN2 (0.50) SMN1; SMN2NOS1SSTR4GAARAB9A
Ammonia Solution, Strong SCHEMBL28044491 0.79 SMN1; SMN2 (0.44) SMN1; SMN2NOS1SSTR4GAARAB9A
SCHEMBL22991009 0.77 SMN1; SMN2 (0.43) SMN1; SMN2NOS1SSTR4GAARAB9A
SCHEMBL441546 0.77 SMN1; SMN2 (0.43) SMN1; SMN2NOS1SSTR4GAARAB9A
SCHEMBL12128459 0.77 SMN1; SMN2 (0.43) SMN1; SMN2NOS1SSTR4GAARAB9A
SCHEMBL127885 0.77 SMN1; SMN2 (0.43) SMN1; SMN2NOS1SSTR4GAARAB9A
SCHEMBL8687634 0.77 PDE4A (0.44) SMN1; SMN2NOS1SSTR4RAB9ACYP3A4
SCHEMBL20047420 0.76 CCR4 (0.41) SMN1; SMN2RAB9AKMT2ANPC1MAPK1
SCHEMBL131590 0.74 SMN1; SMN2 (0.44) SMN1; SMN2NOS1SSTR4GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 US disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 US disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 SMN1; SMN2 2550/4885NOS1 774/4885SSTR4 3594/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 SMN1; SMN2 2671/4885NOS1 787/4885SSTR4 3572/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 SMN1; SMN2 2550/4885NOS1 774/4885SSTR4 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.